SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery

Li-Fong Seet1, Roseline Su, V A Barathi

  • 1Ocular Wound Healing and Therapeutics Group, Singapore Eye Research Institute, Singapore, Singapore.

Plos One
|March 3, 2010
PubMed

Insights

Targeting secreted protein, acidic and rich in cysteine (SPARC) improves glaucoma filtration surgery success. Removing SPARC enhanced wound healing and filtration, suggesting SPARC is a key target for better surgical outcomes.

Area of Science:

  • Ophthalmology
  • Regenerative Medicine
  • Extracellular Matrix Biology

Background:

  • Glaucoma surgery aims to lower intraocular pressure via filtration.
  • Subconjunctival scarring after surgery impedes filtration and long-term success.
  • Current anti-scarring treatments have sight-threatening complications.

Purpose of the Study:

  • To investigate the role of SPARC in post-operative scarring after glaucoma filtration surgery.
  • To evaluate the effect of SPARC deficiency on wound healing and filtration efficiency.
  • To explore SPARC as a potential therapeutic target for enhancing glaucoma surgery outcomes.

Main Methods:

  • Utilized a mouse model of experimental glaucoma filtration surgery.
  • Compared surgical wound survival and filtration in SPARC-null and wild-type mice.
  • Analyzed extracellular matrix composition (collagen, organization) and fibroblast behavior in vitro.

Main Results:

  • SPARC-null mice showed an 87.5% surgical wound survival rate versus 0% in wild-type mice.
  • SPARC deficiency led to increased filtration efficiency, a less collagenous ECM, and looser matrix organization.
  • In vitro studies corroborated in vivo findings regarding ECM remodeling and fibroblast activity.

Conclusions:

  • SPARC deficiency promotes favorable post-operative ECM remodeling, enhancing wound maintenance and filtration.
  • Targeting SPARC presents a promising strategy to improve the success rates of glaucoma filtration surgery.
  • Understanding SPARC's role in ECM regulation is crucial for developing novel glaucoma treatments.

Related Concept Videos